Conference Track

Breast Cancer

Source: CCO Independent Conference Coverage of the 2009 American Society of Clinical Oncology Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Addition of PARP1 Inhibitor BSI-201 to Gemcitabine/Carboplatin Improves Outcomes in Metastatic TNBC
RNA Analysis Identifies Differentially Expressed Genes That Represent Potential Therapeutic Targets for Treating Triple-Negative Breast Cancer
Olaparib Active, Well Tolerated in Heavily Pretreated Patients With Advanced Breast Cancer and BRCA1/BRCA2 Mutations
Neoadjuvant Cisplatin Effective in Small Study of BRCA1-Positive Breast Cancer Patients
MIRROR Study: Higher Axillary Recurrence Rates Observed in Breast Cancer Patients With Micrometastases Who Did Not Receive Axillary Treatment After Sentinel Node Dissection
Tamoxifen Adherence, Concomitant CYP2D6 Inhibitor Use May Affect Breast Cancer Recurrence Risk
BIG 1-98 Substudy: Cognitive Function Better for Adjuvant Letrozole vs Tamoxifen in Early-Stage, Postmenopausal Breast Cancer Patients
Prognostic Ability of uPA/PAI-1 Biomarker Validated for Treatment Decisions in Node-Negative Breast Cancer
70-Gene Expression Profile Predicts Chemotherapy Benefit in Patients With Breast Cancer
Gemcitabine/Docetaxel Efficacy Not Significantly Different vs Capecitabine/Docetaxel in Women With Metastatic Breast Cancer
Trastuzumab-DM1 Active, Safe, and Well Tolerated in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer
RIBBON-1: Addition of Bevacizumab to Standard Chemotherapy Regimens Improves PFS in First-line Treatment of Patients With Metastatic Breast Cancer
Denosumab Produces Consistent Increases in Bone Mineral Density in Women With Breast Cancer and Men With Prostate Cancer Receiving Hormone-Ablation Therapy

Expert Analysis

ASCO 2009: Breast Expert Analysis

Faculty:

William J. Gradishar, MD, FACP
Kathy D. Miller, MD
Mark D. Pegram, MD

Moderator: Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the integration of new agents and treatment strategies into the clinical management of patients with breast cancer
Compare different assays intended to stratify breast cancer patients by risk group
Summarize data from recent studies regarding current standards of care for patients with breast cancer
Describe new data on novel agents and therapeutic approaches for metastatic breast cancer

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: July 21, 2009

Expiration Date: July 20, 2010

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.